Background: Malignant mesothelioma is a rare and aggressive tumor, primarily affecting the pleural lining of the lungs. Our study aims to assess the survival benefit of chemotherapy rechallenge, in patients with no further chemotherapy options, compared to best supportive care, and to identify predictive factors for response to this strategy.Materials and Methods: We retrospectively analyzed data from 163 patients affected by MPM since November 2018. Of these, 41 patients, with advanced stage of disease and previously treated, were evaluated for chemotherapy rechallenge with platinum-pemetrexed regimen or were candidate only to palliative and supportive care. These two populations were compared in terms of overall survival outcomes.Results: When comparing median survival times, a significant difference was observed between the two study groups, with patients treated with platinum-pemetrexed rechallenge reaching approximately 20 months of median survival, while those receiving palliative care only 3 months. Survival percentages at different time intervals show that five months after the decision to undergo rechallenge or begin palliative care, the survival rate for the latter group was 27.27%, which is significantly lower than the 81.57% survival rate in the rechallenge one. Cox regression analysis confirmed rechallenge as a significant predictor of improved survival (HR 0.12, p < 0.001). Conclusion: Our findings suggest a potential survival benefit associated with the use of platinum-pemetrexed rechallenge in selected patients with advanced-stage, pretreated MPM. Further studies with larger cohorts are needed to validate these results.
Background: Pembrolizumab, an anti‐PD‐1 immune checkpoint inhibitor, has transformed the treatment of multiple solid tumors. However, it can rarely cause immune‐related myositis, which may involve limb, bulbar, and respiratory muscles, posing a risk of severe morbidity and mortality. Early recognition and management are essential. We report two cases of pembrolizumab‐induced myositis diagnosed and treated at our institution. A literature search of MEDLINE/PubMed was conducted to identify English‐language case reports, focusing on clinical presentation, diagnostics, management, and outcomes. Cases: The first case involved a 74‐year‐old woman with advanced lung adenocarcinoma who developed grade 4 myositis affecting limb and phonatory muscles; intravenous methylprednisolone combined with IVIG led to full recovery. The second case involved a 78‐year‐old woman with advanced endometrial carcinoma who developed grade 3 limb‐girdle myositis, successfully treated with oral prednisone. Literature review (11 case reports) indicated that most patients were older males with lung cancer, presenting with proximal muscle weakness and elevated CK. Bulbar or ocular involvement was linked to a higher risk of myocarditis and respiratory complications. Early corticosteroid therapy, with IVIG for severe cases, was consistently effective. Conclusions: Pembrolizumab‐induced myositis is a rare but potentially life‐threatening adverse event. Recognition of characteristic clinical features, prompt immunosuppressive therapy, and multidisciplinary care are critical for favorable outcomes. Additional studies are needed to establish standardized diagnostic criteria and optimal treatment protocols.